AGP Picks
View all

Your daily news update on Latin America

Provided by AGP

Latin America News Hub: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Latin America News Hub.

Press releases published on May 5, 2026

Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results
Neuronetics Reports First Quarter 2026 Financial and Operating Results
BridgeBio to Present Primary Results from the Phase 3 CALIBRATE Trial at 2026 ECE
NIOB Expands Pegmatite System with Encouraging Niobium and Rare Earth Exploration Indicators
Fancamp Exploration Appoints Blake Rhodes to its Board of Directors
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026
Electra Therapeutics Announces First Patient Dosed in Phase 1 Study of Ipsoprubart (ELA026) in T Cell Malignancies
Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights
Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update
Shopify Delivers Again as Merchants Clear $100 Billion in Q1 GMV
Morocco Strategic Closes Private Placement for a Total Amount of $7.5 Millions
Corporation de mineraux strategiques du Maroc clôture un placement privé pour un montant total de 7,5 M$
Bullish to acquire Equiniti from Siris in $4.2 billion transaction, creating the global transfer agent for tokenized securities
Fortrea Reports First Quarter 2026 Results
Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting
Cytospire Therapeutics announces oversubscribed £61 million ($83m) Series A financing to advance pipeline of first-in-class pan-gamma delta T cell engagers into clinical trials for the treatment of cancer

Share us

on your social networks:

Sign up for:

Latin America News Hub

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.